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General Summary 
The field of microparticles (MPs) has gained growing interest over the last decade. Numbers 
of papers have come out recently describing molecular or functional characteristics of MPs 
derived from various cells, suggesting in vivo roles for MPs other than being inert side-
products of cellular activation. 
 
The properties and characteristics of MPs released from the surface of activated human 
polymorphonuclear neutrophils (PMN), called ectosomes, will be discussed in Part I. The 
functional implications of these characteristics with regards to cellular interaction of PMN-
ectosomes, in particular with macrophages, and their circulation in blood will be addressed in 
Part II and III, respectively. 
 
As presented in Part I, many neutrophil-derived membrane proteins were translocated to the 
surface of ectosomes. There was no positive or negative selection with regards to 
transmembrane type versus glycophosphatidylinositol-linked type of proteins. Indeed, both 
types had representatives present and absent on the surface of ectosomes. In addition, 
ectosomes exposed several active enzymes on their surface, such as proteinase-3, 
myeloperoxidase, elastase and matrix metalloproteinase-9. The fact that ectosomes are unable 
to maintain the asymmetry of their membrane bilayer was illustrated by the presence of 
phosphatidylserine on their outer membrane leaflet. Ectosomes were also found to bind the 
first component of the classical pathway of complement, C1q; an additional finding that has 
been looked at more in detail in Part III. 
 
Binding assays revealed affinity of ectosomes to endothelial cells as well as macrophages. 
Further analyses of the interaction between PMN ectosomes and human monocyte derived 
macrophages (HMDM) presented in Part II provided data suggesting that ectosomes do not 
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only bind, but are subsequently phagocytosed by HMDM. The sole binding of ectosomes, 
however, was sufficient to induce an anti-inflammatory reprogramming of HMDM. In 
particular, ectosomes dose-dependently counteracted the pro-inflammatory response of 
HMDM to stimuli such as zymosan and LPS. This effect comprised an early increase in the 
release of the anti-inflammatory cytokine TGFβ1 and subsequent downregulation of IL-8, IL-
10 and TNFα secretion. Data obtained using neutralising anti-TGFβ antibodies suggested that 
both phenomena might be causally linked, at least partially.  
 
As alluded to above, ectosomes bind C1q. As presented in Part III, ectosomes were also found 
to activate and fix complement. C3- and C4-fragments were detected on the surface of 
ectosomes after incubation with normal human serum. Using C1q- and C2-deficient serum, 
the ectosome-induced activation of complement could be mainly attributed to the classical 
pathway. Finally, the opsonisation of ectosomes by complement induced their immune 
adherence to erythrocytes. These data suggest that blood-borne ectosomes might be 
sequestered on erythrocytes, a mechanism that might drive their clearance from circulation, 
similarly to immune complexes. 
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General Introduction 
Vesiculation is a ubiquitous cellular phenomenon occurring either intra-cellularly or at the 
cell membrane. As one of numerous forms of vesiculation, ectocytosis is defined as the 
formation and release of right-side out oriented vesicles, ectosomes, directly from the cell 
surface. Ectocytosis is inducible in various eukaryotic cell types, including 
polymorphonuclear neutrophils (PMN), the cell that was focused on here. Stein and 
colleagues initially stimulated PMN with sublytic amounts of complement; in response the 
cells released ectosomes that rid the cells from pore-forming membrane attack complexes1. 
Alongside complement proteins, which triggered ectocytosis, a number of cell-derived 
proteins and lipids were selectively sorted into ectosomes.  
 
Ectocytosis is distinct from another vesiculation process called exocytosis. Exosomes and 
ectosomes, differ in their genesis in that exosomes are preformed and stored vesicles released 
by fusion of so called multivesicular bodies (MVBs) with the cell membrane. Exo- as well as 
ecto-somes can be released from a single cell, as for instance the activated thrombocyte2.  
 
The molecular mechanisms of ectocytosis are still largely unknown, as are the various 
functions ectosomes might have for each cell-type they derived from. However, data have 
accumulated recently suggesting that ectosomes act as vesicular mediators that adopt cell-
specific functions, most of which being of pro-coagulant or pro–inflammatory nature. 
Described functions range from inter-cellular transfer of CCR5 and tissue factor from 
mononuclear cells and platelets, respectively, rapid IL-1β shedding from monocytes, 
endothelial cell and monocyte activation induced by monocytes and platelets, to extracellular 
matrix remodeling by ectosomes released by fibroblasts and chondrocytes3-9. The most 
described features of ectosomes, mainly attributed to ectosomes released by platelets and 
monocytes, are their ability to promote coagulation and activate endothelial cells7,8. 
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Microparticles (MPs), likely to correspond mostly to ectosomes, were shown to directly 
support thrombus formation in a tissue factor dependent manner10,11.  
 
To find, possibly causative, links between MPs, including ectosomes, and homeostasis, MPs 
were traced in serum from patients suffering from various diseases such as sepsis12, severe 
trauma13, paroxysmal nocturnal hemoglobinuria14, diabetes15,16, acute coronary syndromes17 
and lupus18. Although MPs could not be clearly implicated in the pathophysiology of these 
diseases, significant quantitative as well as qualitative changes in MP-counts were observed in 
health versus disease. PMN-ectosome-counts were in particular found elevated in situations 
where PMN are systemically activated, like sepsis. 
 
As our first line of defense, PMN ingest and eventually kill invading pathogens by means of 
potent antimicrobial agents released during the process of degranulation. As this microbicidal 
weaponry largely lacks specificity, it can lead to severe tissue damage if not controlled or 
secluded adequately from surrounding tissue19-21. What role(s) ectosomes, which are released 
from cell activation on, play in PMN’s overall functions is largely unknown. 
 
In a first part, the general properties and characteristics of PMN ectosomes will be outlined, 
with possible implications how ectosomes might implement or modulate PMN functions. The 
second part will deal with a newly characterised role of ectosomes, namely to act as 
downmodulators of the, possibly deleterious, inflammatory response initiated by PMN 
activation, while the last part will focus on the fate of blood-borne PMN ectosomes in 
circulation. As will be described more in depth, ectosomes activate and bind complement and 
subsequently adhere to erythrocytes in a complement receptor 1 (CR1)-dependent manner, 
suggesting that blood-borne ectosomes are behaving, and possibly cleared, similarly to 
immune complexes. 
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 Part I: 
 
Characterisation and Properties of Ectosomes released by Human 
Polymorphonuclear Neutrophils 
 
Abstract 
Human neutrophils release vesicles when activated in vitro and in vivo, in local and systemic 
inflammation. We have suggested that the presence of these vesicles is due to ectocytosis, 
defined as the release of rightside-out oriented vesicles expressing a select set of membrane 
proteins. Herein we have characterised the vesicles released by neutrophils to be ectosomes 
with specific properties. They contained cytosolic F-actin indicating their outside-out 
orientation. They bound AnnexinV suggesting that they expose phosphatidyl-serine, similarly 
to platelet-microparticles. They expressed a subset of cell surface proteins (selectins and 
integrins, complement regulators, HLA-1, FcγRIII and CD66b but not CD14, FcγRII and 
CD87). There was no specificity for transmembrane or glycosyl-phosphatidylinositol-linked 
proteins and unexpectedly L-selectin, known to be cleaved from the surface of activated 
neutrophils, was present. Ectosomes exposed active enzymes released by neutrophils upon 
degranulation (matrix metalloproteinase-9, myeloperoxidase, proteinase 3 and elastase). In 
particular, released myeloperoxidase was able to bind back to ectosomes. The purified 
complement protein C1q and C1q from serum bound to ectosomes as well. Another aspect of 
ectosomes was that they became specifically adherent to monocytic and endothelial cells. 
These observations suggest that neutrophil-derived ectosomes have unique characteristics 
making them candidates to play roles in inflammation and cell signaling. 
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Introduction 
Many eukaryotic cells release vesicles spontaneously or under appropriate stimulation. 
Exosomes are preformed membrane vesicles, which are stored in cellular compartments 
named multivesicular bodies, and secreted when the multivesicular bodies fuse with the cell-
membrane [1]. Many haematopoietic cells including reticulocytes, platelets and leucocytes 
secrete exosomes. For reticulocytes, exosomes mediate the clearance of obsolete proteins such 
as the transferrin receptor. Those released by B-lymphocytes bind firmly to follicular 
dendritic cells and may have the function to present antigens to T-lymphocytes[2]. Exosomes 
of cytotoxic T-lymphocytes may efficiently deliver cytolytic substances to specific targets[3]. 
The structure of such exosomes has now been characterised[4]. 
Beside the release of preformed vesicles, many cells shed small membrane vesicles which are 
formed directly from the cell membrane[5]. This reaction provides for instance protection 
against complement attack, since it allows the removal of the C5b-9 attack complex from the 
cell surface as shown for polymorphonuclear leucocytes (PMNs), oligodendrocytes and even 
erythrocytes[6-8]. Stein and Luzio coined the term ectocytosis for the release of rightside-out 
oriented vesicles (ectosomes) from the surface of PMNs attacked by complement[9]. 
However ectocytosis did not only correspond to the removal of the C5b-9 complex but also to 
a specific sorting of membrane proteins into the shed ectosomes. Enrichment in cholesterol 
and diacylglycerol in the ectosome membrane attested for a specific sorting of lipids as well. 
Hess et al. have provided evidence that when PMNs are stimulated in vitro with formyl-
methionyl-leucyl-phenylalanine (fMLP) or exposed to calcium ionophores, they release small 
vesicles in minutes which have many of the properties expected for ectosomes due to 
complement attack[10]. They expressed a specific set of membrane proteins, including the 
complement receptor 1 (CR1) and in addition proteases such as myeloperoxidase (MPO) and 
elastase suggesting that they may function as extracellular antibacterial organelles. 
Interestingly similar vesicles were isolated from synovial fluids of patients with arthritis, 
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bronchoalveolar lavage fluids in bacterial pneumonia and skin blisters induced by 
Cantharidin, all situations in which PMNs are predominant in the exsudate. In addition, 
electron-microscopy images showed the formation of such vesicles on PMNs by ectocytosis 
minutes after having added the stimulatory agent. 
Various names have been used to describe vesicles released by cells including microparticles, 
particles, microvesicles and vesicles, probably because the mechanism involved in their 
release was not always studied in detail[11-21]. A major fraction of microparticles shed by 
activated platelets corresponds certainly to the definition of ectosomes, as do many others 
released by monocytes, tumor cells, and fibroblasts[13, 20, 22, 23]. Various functions may be 
mediated by ectosomes. Mononuclear cell-released microparticles transfer the chemokine 
receptor CCR5 to cells not expressing it, enabling HIV to infect the recipient cell[15]. The 
rapid secretion of IL-1 β by THP-1 cells is due to the shedding of ectosomes loaded with IL-
1β[14]. Platelet- and monocyte-derived ectosomes induce the coagulation cascade and 
inflammatory processes by activating endothelial cells[11, 20, 24]. Microparticles released by 
leucocytes – mainly PMNs – may activate endothelial cells as well[18]. Such microparticles 
were released by resting leucocytes, but the addition of a stimulus like fMLP increased 
manifold their shedding. Although the nature of the microparticles was not further analysed, 
one might speculate that they were ectosomes. 
Since vesicles released by activated PMNs may have many biological activities, we set out to 
further analyse their structure/function characteristics. The data obtained here provide 
evidence that they are rightside-out oriented, express phosphatidyl-serine, have a very unique 
pattern of in- and out-shuffled cell-membrane proteins, conserve L-selectin which in contrast 
is cleaved from the surface of activated PMNs, acquire a specific panel of proteolytic 
enzymes, bind C1q and can target endothelial as well as monocytic cells. 
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 Material and Methods 
Antibodies 
All antibodies used were monoclonal mouse anti-human antibodies (mAb). The following 
mAb were used: phyco-erythrin coupled mAb directed against CD79 and L-selectin/CD62L 
(Pharmingen / Becton Dickinson), purified mAb against LFA-1/CD11a, Mac-1/CD11b 
(Pharmingen), CD66b, FcγRIII/CD16 (Immunotech, Marseille, France), myeloperoxidase 
(MPO), human leucocyte antigen-I (HLA-I; Dako, Glostrup, Denmark), MCP/CD46, CD59 
(Sanbio, Netherlands), proteinase 3 (PR3) (CLB, Amsterdam, Netherlands), matrix 
metalloproteinase-9 (MMP-9) (R&D Systems, Minneapolis, MN), urokinase plasminogen 
activator receptor (uPAR)/CD87 (Diaclone research, Besançon, France), DAF/CD55 
(Biosource, Camarillo, CA), FcγRII/CD32 (NeoMarkers, Fremont, CA), C1q (Quidel, San 
Diego, CA), FLAG-peptide (IgG1 control directed against the octa-peptide N-Asp Tyr Lys 
Asp Asp Asp Asp Lys-C) (Eastman Kodak Company, New Haven, CT), and CR1/CD35 
(clone 3D9). All non-labeled mAb were biotinylated prior to use (see below). 
 
Biotinylation of monoclonal antibodies 
Ab were incubated for 1 h at 22°C in the presence of 1 µL biotin-ester (10 mg/mL in 
DMSO)/50 µg of antibody in sodium borate buffer (0.1 M, pH 8.8), final volume 2 mL. 
Biotinylated mAb were dialyzed against phosphate buffered saline (PBS) overnight at 4°C in 
a Slide-A-Lyzer® 10,000 MW cut-off dialysis cassette (Pierce, Rockford, IL). Biotinylated 
mAb were recovered and concentrated with microsep™ centrifugal concentrators (10,000 
MW cut-off, Pall Filtron Corp.) to a final mAb-concentration of 250 µg /mL. Biotinylated 
mAb were stored at 4°C. 
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Isolation and stimulation of PMNs 
PMNs were isolated from fresh buffy coats of normal donors according to the technique 
described previously[10]. Briefly, a fresh buffy coat obtained from approximately 400 mL of 
normal donor blood was diluted 1/1 (v/v) with PBS-ethylenediaminetetraacetic acid (EDTA) 
(2 mM), mixed gently with 0.25 vol of 4% Dextran T500 (Amersham Pharmacia Biotech, 
Dübendorf, Switzerland), and left for 30 minutes for erythrocyte sedimentation. The 
leucocyte-rich supernatant (S/N) was aspirated and centrifuged for 10 minutes at 200g. The 
pellet was resuspended for 1 minute in 9 mL of ultrapure water to lyse erythrocytes. 
Isotonicity was restored by addition of 3 mL of KCl (0.6 M) and 40 mL of NaCl (0.15 M). 
Cells were then centrifuged 10 minutes at 350g, and resuspended in 20 mL of PBS-EDTA (2 
mM). This suspension was layered over 20 mL of Ficoll-Hypaque (Sigma, St-Louis, MO) and 
centrifuged for 30 minutes at 350g. The PMN-rich pellet was recovered and washed twice in 
PBS-EDTA (2 mM). All manipulations were performed at 4°C, thus minimizing PMN-
activation. 
For stimulation, PMNs (107 cells/mL) were diluted 1/1 (v/v) in pre-warmed (37°C) RPMI 
1640 (Life Technologies, Basel, Switzerland) with fMLP, ionomycin, or PMA (1 µM, 5 µM, 
10 nM final concentrations respectively, all from Sigma, St-Louis, MO), and incubated for 20 
minutes at 37°C in a water bath. Cell activation was stopped by putting the cell suspensions 
on ice, and PMNs were removed by centrifugation (two consecutive runs, 20 minutes each, 
4000g at 4°C). The supernatant (S/N) was concentrated ~50-fold with Centriprep® centrifugal 
filter devices (10,000 MW cut-off, Millipore Corporation Bedford, MA) and stored in aliquots 
at -80°C until use. 
 
Transmission electron microscopy of ectosomes / negative staining 
After ultracentrifugation, ectosomes were resuspended in PBS and then fixed in 1% 
glutaraldehyd (final concentration) for 20 minutes at room temperature. Ectosomes were then 
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adsorbed to parlodion-coated copper grids. After washing, samples were stained with 2% 
uranylacetate before being observed in a Philips Morgani 268 D transmission electron 
microscope operated at 80kV. 
 
Fluorescence Activated Cell Scanning (FACScan)-analysis of ectosomes 
Samples were analysed with a FACScan flow cytometer from Becton-Dickinson (Mountain 
View, CA). The light scatter and fluorescence channels were set at logarithmic gain. An 
acquisition threshold was set on the forward scatter in order to reduce background-signal. In 
order to analyse ectosomes by FACScan, concentrated PMN-S/N (see above) was 
ultracentrifuged for 30 minutes at 160,000g/4°C in a SW55ti rotor (Beckman Instruments Inc., 
Palo Alto, CA). Pelleted ectosomes were washed twice with 0.9% NaCl (B. Braun Medical 
AG, Emmenbrücke, Switzerland) and incubated at 22°C for 10 minutes in 100 µL 0.9% 
NaCl/10% normal mouse serum (ultracentrifuged prior to use in order to remove aggregates) 
(Cedarlane laboratories Ltd., Hornby, Canada). Blocked ectosomes were labeled with 5 
µg/mL of biotinylated mAb, or a 1/200 dilution of fluorochrome labeled mAb, in FACScan 
buffer (PBS, 1% bovine serum albumin (BSA), 10 mM sodium azide) for 10 minutes at 22°C. 
Ectosomes were then pelleted by ultracentrifugation (30 minutes, 160,000g/4°C), and washed 
twice in FACScan buffer. Bound biotinylated antibodies were revealed with 2 µL 
streptavidin-phyco-erythrin/100 µL FACScan buffer (incubated for 10 minutes at 22°C). 
Labeled ectosomes were then resuspended in 200 µL 0.9% NaCl and analysed on a FACScan. 
Forward (FSC) and side scatter (SSC) as well as fluorescence channels (FL1 and FL2) were 
set on logarithmic scales. 
 
Membrane labeling of ectosomes 
An amphiphilic cell linker dye kit (PKH67, Sigma, St-Louis, MO) was used, following the 
labeling procedure provided by the manufacturer. Briefly, ectosomes resuspended in 200 µL 
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Diluent C were incubated with 200 µL diluent C/dye solution (dye diluted 1/200) for 30 
seconds at 22°C, with gentle shaking. 1 mL RPMI 1640 (without phenol red) was added to 
stop the reaction. Labeled ectosomes were separated from the remaining unbound dye by 
ultracentrifugation (45 minutes, 160,000g/4°C) and washed with 0.9% NaCl. In order to avoid 
capping of Ab with dye, membrane-labeling was made prior to antibody-binding steps. 
 
Binding of annexin V to ectosomes 
Ectosomes were isolated from concentrated PMN-S/N and washed as described above. 
Washed ectosomes were resuspended in either 100 µL 0.9% NaCl, or AnV binding buffer (10 
mM Hepes/NaOH, 140 mM NaCl, pH 7.4) with or without 2.5 mM CaCl2. 2µL AnV-FITC or 
AnV-biotin were added to each reaction. After incubation for 10 minutes/22°C ectosomes 
were washed twice in their respective buffer. When using AnV-biotin, a second step with SA-
PE was performed as described above. Ectosomes where then resuspended in 200 µL 0.9% 
NaCl and analysed by FACScan. 
 
Western blot analysis/zymography of matrix metalloproteinase-9 
Western blotting and zymography were performed after separation of ectosomal proteins by 
7.5% sodium-dodecylsulfate polyacrylamide-gel-electrophoresis (SDS-PAGE). For 
zymography, gels were supplemented with gelatin (1 mg/mL) (Sigma, St-Louis, MO). For 
zymography, gels were incubated in zymography buffer (50 mM Tris-HCl, 5 mM CaCl2, 1 
µM ZnCl2) overnight at 37°C and stained in Brilliant Blue. Recombinant active MMP-9 was 
used as positive control (Oncogene, Cambridge, MA; 0.5 µg/lane). For Western blots, gels 
were transferred onto nitrocellulose membranes, which were blocked overnight at 4°C in 
PBS/6% skimmed milk powder. Membranes were then washed briefly in PBS/0.01% Tween 
20 and incubated with anti-MMP-9 antibodies (0.5 µg/mL in PBS/1% BSA) for 1 hour at 
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22°C. Membranes were then washed three times for 10 minutes in PBS/0.01% Tween 20 and 
bound mAb detected using goat anti-mouse antibodies. Finally, membranes were incubated 
for 45 minutes in horse-radish-peroxidase coupled streptavidin diluted in PBS-BSA. 
Detection was by enhanced chemi-luminescence (ECL kit, Amersham Pharmacia Biotech) 
with BioMax™ films (Kodak, Rochester, NY).  
Alternatively, to check for the presence of MMP-9 inside ectosomes we probed whole 
ectosomes as well as sonicated ectosomes with an EnzChek Gelatinase/Collagenase Assay 
kit (Molecular Probes, Eugene, OR), following the manufacturer’s indications. 
 
MPO and elastase activity assays 
Enzymatic activity of MPO was determined in a colorimetric assay using whole ectosomes, 
where 50 µL of orthophenyldiamine-solution (2 µg in 5 mL citrate-phosphate buffer, pH 5, 
with 2 µL of 35% H2O2) were incubated with 100 µL of the sample to be tested. The reaction 
was stopped using 2.5 M H2SO4, and the absorbance measured with a microplate reader 
(Thermo Max, Molecular Devices, Menlo Park, CA) at 490 nm[25]. Enzymatic activity of 
elastase was analysed using an EnzChek Elastase Assay kit (Molecular Probes, Eugene, 
OR). Where indicated elafin (a specific inhibitor of elastase, kindly provided by Dr. Dougie 
Paterson, Zeneca Pharmaceuticals, GB) was used at a concentration of 30 µg/mL. To check 
for the presence of elastase inside ectosomes we assessed elastase activities of whole 
ectosomes as well as sonicated ectosomes with this kit. 
 
Detection of ectosomes in whole blood 
Fresh citrate anti-coagulated blood was obtained from normal blood donors. For activation, 5 
mL of whole blood was incubated with 1 µM fMLP for 20 minutes at 37°C. Immediately after 
activation, cells were removed by centrifugation (10 minutes, 1000g, 25°C) and S/N stored at 
-80°C until use. 
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For isolation of blood-borne vesicles, including ectosomes, plasma from activated whole 
blood was ultracentrifuged as for PMN-S/N. Vesicles were then stained with AnV and mAb 
against CD66b. Fluorescence of vesicles was detected by FACScan-analysis. 
 
Binding of exogenous MPO to MPO-deficient ectosomes 
MPO-deficient as well as normal PMNs were isolated and activated as described above. 
Ectosome-free normal PMN-S/N was kept and stored until further use at 4°C. After a washing 
step with 0.9% NaCl, MPO-deficient ectosomes were incubated 10 minutes at 22°C with 200 
µL of ectosome-free normal PMN-S/N, 100 ng of purified MPO added to 200 µL PBS, or 200 
µL PBS. Ectosomes from normal donors were incubated with PBS only. Ectosomes were then 
washed twice and stained for MPO with biotinylated mAb anti-human MPO, followed by 
streptavidin-phyco-erythrin as described above. Labeled ectosomes were analysed by 
FACScan-analysis. 
 
Binding of C1q to ectosomes 
Ectosomes were isolated as described above. Ectosomes were then ultracentrifuged and 
incubated, after gentle resuspension, for 30 minutes at 4°C in 100µL of 0.9% NaCl alone or 
0.9% NaCl supplemented with either 1µg of purified C1q (Calbiochem, La Jolla, CA), normal 
human serum (1/10 final dilution) or heat-inactivated normal human serum (1/10 final 
dilution; heat inactivation: 30 minutes at 56°C). The binding of C1q was then detected using a 
biotinylated anti-C1q antibody and streptavidin-phyco-erythrin, as described for all other 
FACScan-analyses of ectosomes. 
 
Cell cultures 
All cultures were maintained in 5% CO2 at 37°C and medium replaced every second day. 
Human umbilical vein endothelial cells (HUVEC) were obtained from Clonetics (San Diego, 
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CA) and cultured in medium consisting of M199 supplemented with 20% fetal calf serum, 
100 U/mL penicillin, 100 µg/mL streptomycin, 100 µg/mL heparin and 50 µg/mL endothelial 
cell growth supplement (Sigma, St-Louis, MO). Cells were split by trypsinization (0.025% 
trypsin solution) when confluent. THP-1 cells were cultured in RPMI 1640 medium 
supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 2 
mM L-glutamine. 
 
Binding assays of ectosomes to human erythrocytes, endothelial and phagocytic cells 
Confocal microscopy: Ectosomes were prepared and labeled as described above. HUVEC (of 
the second to fifth passage) were cultured on gelatin-coated culture slides. THP-1 cells were 
cultured on uncoated culture slides for three days in the presence of 160 nM PMA for 
differentiation into phagocytic cells. HUVEC and THP-1 cells were then incubated with 
labeled ectosomes for 30 minutes washed three times with medium and analysed (Zeiss 
microscope). For these experiments, ectosomes were counted by FACS analyses, gating on 
CD66b positive events. Incubations were performed using a cell to ectosome ratio of 1:10. 
FACScan analysis: Erythrocytes were isolated from freshly drawn EDTA-anticoagulated 
blood from a normal donor by dextran sedimentation. Labeled ectosomes were incubated for 
30 minutes at 37°C with the different cell types. Binding assays were performed using 106 
erythrocytes/mL in a final volume of 100 µL. The same concentration was used for HUVEC 
and THP-1 cells. For blocking experiments, prior to adding labeled ectosomes, cells were 
incubated for 10 minutes with the indicated proportions of unlabeled ectosomes. Cells were 
then washed, resuspended and analysed by FACScan. As mentioned above, incubations were 
performed using a cell to ectosome ratio of 1:10. 
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Two-dimensional gel electrophoresis and data analysis 
A commercial sigmoidal immobilised pH gradient (IPG) going from pH 3.5 to 10.0 was used 
for first dimensional separation. After equilibration, IPG gel strips were transferred for the 
second dimension onto vertical gradient slab gels (9-16% T, 2.6% C) and run with the 
Laemmli-SDS-discontinuous system. Protein detection was done using a sensitive 
ammoniacal silver stain or Coomassie Brilliant Blue R-250 (0.1% w/v) and methanol (50% 
v/v) for 30 minutes. Destaining was done in a solution containing methanol (40% v/v) and 
acetic acid (10% v/v). Gels were then scanned using a laser densitometer (APB, Uppsalla). 
The 2-D PAGE image computer analysis was carried out using the MELANIE 3 software 
package (GeneBio, Geneva, CH). Optical density, area and volume were computed and 
related to protein concentration. Also, the relative optical density and relative volume was 
calculated in order to correct for differences in gel-staining. Differentially expressed proteins 
were determined by differential analysis and significance in differences was tested using 
Student T-test. A p<0.05 was considered significant. 
 
Protein identification by tandem mass spectrometry (MS) 
Coomassie blue 2-DE spots were excised from the 2-D gel and destained with 100 µL of 30% 
acetonitrile in 50 mM ammonium bicarbonate at 37°C for 45 minutes. The S/N was discarded 
and the gel spots dried in a SpeedVac for 30 minutes. The gel spots were rehydrated with 10 
µL of a solution containing 6.25 ng/µL of porcine trypsin in 50 mM ammonium bicarbonate 
buffer for 45 minutes on ice. Digestion was carried out overnight at 37°C. Resulting peptides 
were extracted at 22°C by two sequential extraction steps of 20 minutes. The first extraction is 
performed with 20 µL of 1% TFA and the second one with 20 µL of 0.1% TFA in 50% 
acetonitrile. The combined extracts were concentrated in a SpeedVac to approximately 2 µL, 
redissolved in 30-40 µL of 0.1% TFA and dried again down to approximately 2 µL. Then 5 
µL of a 0.1% HCOOH solution was added. 5 µL of the peptide extract were loaded onto a 75 
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µm diameter and 10 cm long C18 micro-column. Peptides were eluted at 400 nL/minute by a 
linear gradient of acetonitrile in 0.1% HCOOH and directly analysed by nanoESI-MS/MS 
conducted on a Q-TOF mass spectrometer from Micromass (Manchester, UK). MS/MS 
spectra were acquired by automatic switching between MS and MS/MS mode by the 
instrument. Acquired fragment ion spectra were searched by Mascot against databases such as 
SWISS-PROT, TrEmbl or ESTs databases. 
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Results 
Qualitative Analysis of ectosome-preparations 
Ectosome-preparations were tested for their quality and purity by electron microscopy. As 
shown in Figure 1 a), ectosome-preparations did not present any major impurities. Figures 1 
b), c) and d) represent higher magnification pictures of ectosomes, showing again the absence 
of any microparticles other than ectosomes in our preparations. The size heterogeneity of 
ectosomes is documented in Figure 1 b), which shows ectosomes of different sizes, located 
next to each other (arrows). 
 
 
a) b) 
c) 
d) 
Figure 1: Electron microscopy of ectosomes 
a) Overview on the purity of ectosome-preparations used for analyses. Size bar: 500 nm. b), c) 
and d) higher magnification picture of ectosomes. All size bars: 100 nm. 
 
Flow-cytometry-based detection of PMN-derived vesicles 
The vesicles released by PMNs activated with 1µΜ fMLP were recovered after 20 min of 
incubation at 37°C by differential centrifugation. First PMNs were pelleted by centrifugation 
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at 4000g for 2X20 min, the supernatant containing the vesicles was then ultracentrifuged at 
160,000g for 30 min. The pelleted vesicles were resuspended and could be dissociated by 
gentle mixing in 0.9% NaCl. By flow-cytometry such vesicles were found to form a distinct 
FSC/SSC-population. The size heterogeneity was reflected by a simultaneous scattering 
towards higher FSC and SSC values. A typical FSC/SSC plot of purified vesicles and the 
standard gate as set for their analysis is shown in Figure 2A. The detection of synthetic 
fluorescent beads of 200 nm diameter within the gate set for vesicles confirmed their 
approximate size (of range 50 to 200 nm)[10] (data not shown). 
R1
AnV-FITC + Ca2+ 
AnV-FITC in NaCl 
AnV-FITC – Ca2+ 
Ectosome autofluorescence 
Ectosomes + dye 
Si
de
 li
gh
t s
ca
tte
r 
Ec
to
so
m
e 
co
un
ts
 
Forward light scatter 
A 
Ec
to
so
m
e 
co
un
ts
 
Fluorescence intensity 
C
Fluorescence intensity 
Figure 2: Detection of ectosomes by
FACScan 
Scatter dot plot of ectosomes derived from
activated normal PMNs. The gate (R1)
contains the majority of ectosomes. (B)
Fluorescence histogram of ectosomes
before (thin line) and after (thick line)
membrane labeling. (C) Fluorescence
histogram of AnV-FITC stained
ectosomes. Ectosomes were incubated
with AnV in binding buffer (thick line),
calcium depleted binding buffer (dotted
line), or 0.9% NaCl solution (thin line). 
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Using an amphiphilic, membrane-interchelating dye, particles within the above-defined gate 
uniformly acquired fluorescence (Figure 2B). Interestingly the intensity of the fluorescence 
correlated directly with both FSC and SSC, indicating that larger vesicles had taken up more 
dye (data not shown).  
Under many circumstances vesicles released by activated cells express phosphatidyl serine, a 
marker for the loss of lipid-membrane assymetry[5]. By flow cytometry we could show that 
annexin V (AnV), which binds PS in a calcium-dependent manner, bound to the vesicles 
(Figure 2C). This binding was prevented by depleting calcium from the buffer or using a 
saline solution deprived of calcium. Thus the vesicles exposed negatively charged 
phospholipids, very likely to be phosphatidyl-serine. An AnV/membrane-dye double-labeling 
indicated clearly that AnV binding was present on all lipid-expressing vesicles, with the 
binding of AnV correlating directly with the size of the vesicles. 
 
Protein expression by PMN-derived vesicles  
We then set out to analyse the proteins expressed by these vesicles by two-dimensional gel-
electrophoresis (proteome) (Fig 3A). We identified actin and annexin III as two of the major 
proteins present by comparing 2-DE patterns of vesicles with a 2-DE library (computer-aided) 
and by sequencing (Fig 3A-B). Actin is a cytosolic protein, which would confirm that the 
vesicles form by budding from the cell-membrane and incorporate some cytoskeletal 
components of the cytosol. By flow-cytometry phalloidin, which binds F-actin, was used to 
confirm the presence of actin in the vesicles. Interestingly phalloidin did react with 
permeabilised vesicles only, and the intensity of staining was proportional to the 
concentration of the detergent used (Fig 3C). By contrast, intact vesicles did not bind 
phalloidin. Thus actin was only present inside the vesicles, suggesting that they were 
rightside-out oriented. Permeabilisation did not alter the binding of mAb specific for proteins 
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present on the surface of ectosomes (described below), thereby ruling out the possibility that 
the detection of actin was due to phalloidin trapped inside ectosomes. 
   
   
50
   
  7
0 
   
10
0 
 2
00
  
 C
 un
ts
 
Phalloidin/ectosomes 
Phalloidin/permeabilised ect. (0.05%) 
Phalloidin/permeabilised ect. (0.1%) 
A
 
 
 
r 
 
 
 
 
B 
 
F
(A
w
a
se
a
p
a
li
u
 
In
a
tr
a
v
P
w
    
10
   
   
   
   
 2
0 
   
   
   
   
 3
0 
   
 
annexin III 
Fluorescence intensity 
C
el
l c
oM
igu
) 2
ere
naly
arc
nd a
erce
naly
ne: 
sing
 pa
gain
ans
nd G
esic
MN
ell.4.0   4.5  5.0       5.5      6.0   6.5    7.0     8.0 10 re 3
D-
 ide
zed
h. P
nn
nta
zed
0.0
 th
rall
st d
me
PI
les
s a
 In actinAnnexin III 
pI 
Actin 
: Detection of ectosome-associated annexin III and intraectosomal actin 
GE of ectosomal proteins. By mass spectrometry, protein spots indicated by arrows 
ntified as actin and annexin III, as indicated. (B) Trypsin-digested excised spots were 
 by tandem mass spectrometry and ion spectra interpreted with the Mascot database 
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 in permeabilizing buffers containing increasing concentrations of detergent (thin 
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el we analysed the expression of proteins on the surface of the vesicles by using mAb 
ifferent PMN-proteins using purified PMNs as controls. With this approach, many 
mbrane [HLA-I, CD35 (CR1), CD11a, CD11b, CD62L (L-selectin), CD46 (MCP)] 
-anchored proteins [DAF, CD59, CD66b, CD16 (FcγRIII)] were identified on the 
 (Table 1). Of particular interest was the presence of L-selectin, which is cleaved off 
t the time of cell activation, but which is clearly lost from PMNs by vesiculation as 
addition to proteins derived from the PMN cell-surface, vesicles also expressed  
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PMN-proteins not detected on 
ectosomes 
PMN-proteins detected on 
ectosomes 
Example shown: uPAR/CD87 
 
 
Example shown: HLA-1 
Other proteins not detected: 
 
Receptors: CD14 and 
FcγRIII/CD32. 
Other proteins detected: 
 
Receptors: CR1/CD35, LFA-
1/CD11a, Mac-1/CD11b, 
FcγRIII/CD16 and L-selectin. 
Enzymes: Myeloperoxidase, 
Elastase, MMP-9 and PR3. 
Complement proteins: 
MCP/CD46 and CD59. 
Other: CD66b 
 
 
Table 1: Summary of PMN-proteins found on ectosomes by FACScan analysis. 
In FACS histograms, dotted line represents fluorescences of ectosomes (in R1) incubated with 
isotype-control mAb and thick line represents fluorescences of ectosomes (in R1) incubated 
with mAb against the mentioned antigen. 
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  Ectosomes Cell 
membrane 
Azurophilic 
granules 
Specific 
granules 
Gelatinase 
granules 
Secretory 
vesicles 
Protein 
type 
HLA-1 + + - - - - TM 
CR1/CD35 + + - - - + TM 
CD11a + + - - - - TM 
CD11b + + - + + + TM 
L-selectin + + - - - - TM 
MCP/CD46 + + - - - - TM 
CD66b + + - + - - GPI 
DAF/CD55 + + - - - - GPI 
FcγRIII/CD16 + + - - - + GPI 
CD59 + + - - - - GPI 
uPAR/CD87 - + - + + + GPI 
CD14 - + - - - + GPI 
FcγRII/CD32 - + - - - - TM 
MPO + - + - - - soluble 
elastase + - + - - - soluble 
proteinase 3 + - + + - + soluble 
MMP-9 + - - + + - soluble 
  
 
 
Table 2: Cellular localisation of proteins analysed for their presence on ectosomes. 
Legend: +: present, -: absent, TM: transmembrane anchored protein, GPI: glycosyl-
phosphatidylinositol linked protein. 
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elastase, proteinase 3 (PR3), MPO and MMP-9, all stored within granules of resting PMNs 
(Table 2), with some enzymes producing a more intense staining than others. Furthermore, by 
double-labeling we could confirm that the fluorescence for MPO was directly proportional to 
the fluorescence obtained after membrane-staining (amphiphilic dye; Fig 4C). Electronic 
compensation during acquisition of double-staining data was used to reduce the spectral 
overlap of both fluorochromes. An identical proportional increase was seen when testing 
CD46 (MCP) versus AnV (Fig 4B).  
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Figure 4: FACScan analysis of 
protein/protein and membrane/protein 
double-labeled ectosomes 
(A) Isotype-control double-labeled
ectosomes are shown on the left,
CD35/CD66b double-labeled ectosomes
on the right. (B) Isotype-control labeled
ectosomes are shown on the left,
AnV/CD46 double-labeled ectosomes on
the right. (C) Isotype-control labeled
ectosomes are shown on the left,
membrane dye/MPO double-labeled
ectosomes on the right. All data represent
fluorescence intensities of ectosomes
gated in R1. 
Other double-labeling studies suggested that this was a general rule for ectosomal proteins, 
i.e. the intensity of fluorescence being proportional to membrane-staining. Indeed we tested 
both CD16 (FcγRIII) and elastase versus AnV and obtained similar results (data not shown). 
In fact, every double-labeling suggested the same general rule: all staining-intensities 
correlated positively, even when two membrane proteins were plotted versus each other (e.g. 
CR1/CD66b, Figure 4A). In addition, the correlation between signal intensities of detected 
 28
proteins and/or membrane confirmed that the detection of protein was limited by the size of 
the vesicles. Even the smallest vesicles were shifted by the specific label, although this shift 
was sometimes minimal (membrane-dye single-positive; e.g. Figure 4C, right plot, lower right 
hand side quadrant). Therefore, large vesicles are likely to be biologically more active. 
Furthermore, we could not detect different populations of vesicles, i.e. we found no 
discrepancies between all the markers used. By contrast, the vesicles (even when gating on 
their larger fraction only) did not express detectable amounts of CD14, CD32 (FcγRII) and 
CD87 (urokinase plasminogen activator receptor, uPAR), while the same molecules could 
clearly be detected on PMNs (data not shown). 
 
Taken together, the data indicated that the vesicles have all the hallmarks of ectosomes as 
described by Stein and Luzio[9]. However, one additional aspect was uncovered in the sense 
that ectosomes may acquire enzymes, which are released by degranulation of PMNs at the 
time of their activation.  
 
Binding of MPO to ectosomes  
Taking advantage of an MPO-deficient individual the mechanism by which MPO (stored 
within the azurophilic granules of resting PMNs) may become translocated to the membrane 
of ectosomes was studied. Firstly, purified MPO in normal buffer (PBS) bound to MPO-
deficient ectosomes in a dose-dependent and saturating manner (data not shown). The 
fluorescence intensity reflecting the presence of MPO on ectosomes reached the level of 
normal ectosomes (Figure 5A-B). Secondly, using a more physiological assay, MPO from 
ectosome-free S/N from degranulated PMNs of normal donors (containing soluble MPO) 
bound to a similar extent to MPO-deficient ectosomes (Figure 5B), indicating that at least a 
fraction of MPO rebinds to the surface of the ectosomes. 
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The presence of matrix metalloproteinase-9 (MMP-9) was confirmed by Western blot of 
ectosomal proteins (Fig 5D, upper panel). The migration of the monomeric form of MMP-9 
from ectosomes was slightly different from the control (active) MMP-9, suggesting that it was 
in its pro-form. We obtained three distinct bands of apparent molecular weights 92kDa, 130 
kDa and 220 kDa, which seem to correspond to all three storage-forms of MMP-9 in PMNs, 
namely pro-MMP-9 monomer, the MMP-9/lipocalin heterodimer and the MMP-9 homodimer, 
respectively. All forms of MMP-9 were then shown to be enzymatically active by their 
capacity to degrade gelatin in a zymographic assay (Fig 5D, lower panel; only monomeric 
MMP-9 shown).  
Whole ectosomes had elastolytic activity, which was in part inhibitable by elafin, a specific 
inhibitor of elastase/PR3 (Fig 5C). Elastase as well as MMP-9 activities remained unchanged 
when ectosomes were first lysed by sonication (data not shown). These data suggest that 
elastase/PR3 and MMP-9 were present almost exclusively on the surface of ectosomes and 
not stored inside ectosomes. 
 
Ectosomes released by PMNs can be identified in whole blood 
An important aspect was to see whether the reactions observed with purified PMNs would be 
similar in a more physiological environment, and would correspond to the activation of 
circulating PMNs as described in several clinical situations[26-28]. Therefore, PMN-
activation in whole-blood was simulated in vitro, and a system to specifically trace PMN-
derived ectosomes was established. fMLP was added to citrate-anticoagulated blood and 
incubated for 20 minutes at 37°C. Thereafter cells were removed and the S/N applied to 
ultracentrifugation. The pellet was redissolved and analysed by FACScan. A typical FSC/SSC 
plot of microparticles obtained from activated whole blood is shown in Figure 6A. 
Phosphatidyl-serine expressing membrane-particles were traced by staining with AnV, and 
PMN-derived ectosomes were distinguished from non-PMN-derived microparticles by tracing 
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the PMN-specific protein CD66b. As shown in Figure 6B, a majority of particles obtained 
from the S/N of activated whole-blood was binding AnV (≈70%). In contrast, only a sub-
population of AnV-binding particles also expressed CD66b (≈13% of the total events or 
≈20% of AnV positive events; Figure 6C). The AnV/CD66b-double-positive population (i.e. 
PMN-derived ectosomes) localised in a distinct region of the FSC/SSC plot (Figure 6C), 
comparable to the one delimited by ectosomes obtained from isolated PMNs (Figure 2A). 
This gate was devoid of CD66b negative, i.e. non-PMN-derived particles, indicating that 
PMN-derived ectosomes exhibit particular biophysical characteristics distinguishing them 
from other blood-borne microparticles by FACScan. CD66b-positive (PMN-derived), as well 
as single-, AnV-positive ectosomes could be detected using the same technique in control 
plasma (without fMLP), however, in significantly lower numbers than in the supernatant of 
blood stimulated with fMLP (data not shown). This finding is consistent with previous reports 
describing the presence of ectosomes in the circulation of healthy individuals[19, 29]. 
 
Figure 6: Detection of ectosomes 
in whole blood 
(A) Scatter dot plot of total micro-
particles (MP) derived from fMLP
stimulated whole blood. (B) The
dotted and filled lines in the
histogram correspond to unstained
and AnV-FITC stained blood MP,
respectively. Gate R1 includes all
AnV-positive MP. The scatter dot
plot represents FSC/SSC
characteristics of AnV-positive MP
only (gated on R1). (C) The dotted
and filled lines in the histogram
correspond to unstained and anti-
CD66b stained MP, respectively.
Gate R2 includes all CD66b-positive
MP. The scatter dot plot represents
FSC/SSC characteristics of CD66b
positive MP only (i.e. ectosomes,
gate R2). 
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Ectosomes bind to the surface of selective cell-types 
Since ectosomes express various adhesion proteins including L-selectin, we tested for their 
capacity to bind to endothelial cells (HUVEC) and a human monocytic cell line (THP-1) 
using human erythrocytes as controls. Ectosomes were labeled with membrane dye and 
incubated with the aforementioned cell-types. Thereafter cells were washed extensively in 
order to release weakly associated ectosomes. As assessed by FACScan analysis, both 
HUVEC and THP-1 cells bound ectosomes in a dose dependent, and saturable manner. 
Competition for binding-sites on HUVEC and THP-1 cells was revealed by their 
displacement with unlabeled ectosomes (Figures 7A-B), a displacement which was 
concentration dependent. No binding of ectosomes to erythrocytes was observed (Figure 7E). 
This was in contrast to liposomes [70% PS, 30 % phosphatidyl-choline (PC)], which were 
found to bind nonspecifically to the cell-surface of all three cell-types (data not shown). Using 
confocal microscopy, fluorescent ectosomes were visualised as discrete spots on the cell-
surface of both HUVEC and THP-1 cells, confirming the data obtained by FACScan (Figure 
7C-D). 
 
Binding of C1q to the surface of ectosomes 
The binding of C1q to apoptotic cells/bodies has been shown to be one of the central reactions 
which allows the efficient removal of apoptotic cells by phagocytes. To see whether C1q 
would also bind to ectosomes, we incubated them for 30 minutes at 4°C with or without 
purified C1q (10µg/ml final concentration) in 0.9% NaCl, normal human serum or heat-
inactivated normal human serum  (1/10 final dilutions). C1q was detected on ectosomes after 
incubation with purified C1q and more interestingly after incubation with whole serum, in 
which C1q is associated in the macromolecular C1 complex (Figure 8). No signal was 
detected in the control heat inactivated serum or in the absence of C1q. 
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Figure 8: Binding of C1q to ectosomes 
FACScan histogram of ectosomes incubated for 30 minutes at 4°C in the presence or absence 
of C1q and subsequently probed with a biotinylated anti-C1q mAb and streptavidin-phyco-
erythrin. The bold and short dotted lines represent ectosomes incubated in 0.9% NaCl in the 
absence and presence of 10µg/mL purified C1q, respectively. The thin and long dotted lines 
represent ectosomes incubated in 0.9% NaCl in the presence of 10% (final dilution) normal 
human serum and heat-inactivated normal human serum, respectively. 
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Discussion 
In the present studies we analysed biochemical and immunological characteristics of vesicles 
released by activated PMNs. The main findings were that these vesicles corresponded in 
many ways to ectosomes as described by Stein et al., since they expressed a selected set of 
membrane proteins, and were rightside-out oriented vesicles containing cytoplasmic 
proteins[9]. They had however a series of properties not described yet for PMN-ectosomes, 
i.e. they expressed phosphatidyl-serine in the outer leaflet of their membrane similarly to 
apoptotic bodies and to vesicles released by platelets, they acquired enzymes originating from 
azurophilic granules on their membrane, and they targeted endothelial cells as well as 
monocytic THP-1 cells. 
 
Using electron-microscopy we have previously shown that the vesicles shed by PMNs had a 
size of approximately 50 to 200 nm[10]. Here, the vesicles were analysed by FACScan, which 
allowed us to further define them. A distinct population of membrane-particles was clearly 
identified and when compared to scattering-characteristics of synthetic beads (diameter 200 
nm and bigger) these membrane-particles/vesicles had the same wide range of sizes as seen 
on the electron-microscopy images[10]. All the events registered in the defined FACScan 
window incorporated a lipid marker for membranes indicating that no artifacts such as 
aggregates of proteins were present. The intensity of labeling with this marker was directly 
correlated with the size of the vesicles confirming that the lipid-membrane increased together 
with the size of the vesicle as estimated from the scattering data. Interestingly all positive 
protein and lipid markers used showed the same increase in fluorescent intensity with the 
increase in size, suggesting that vesicles may differ in size but not in their general membrane 
composition. Thus activated PMNs shed one type of vesicles, which might however not have 
identical properties because of their size.  
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Ectosomes should contain cytosolic proteins. The presence of actin within and not on the 
surface of PMN-derived vesicles confirmed that they are released as intact rightside-out 
membrane-vesicles with a cytosolic content. Actin has been shown to be associated with 
vesicles released by mechanically-stressed fibroblasts, where it is thought to be involved in 
vesicle budding[13]. Actin also has been proposed to play a role in specific protein retention 
during in vitro budding of erythrocyte-vesicles[30]. It is likely that actin together with other 
cytoskeletal components plays a role in the formation of PMN-derived ectosomes as well. 
Stimulatory agents induce the shedding of membrane-vesicles mainly by inducing first an 
influx of calcium into the cell, which is followed by the scrambling of lipids between the two 
layers of the cell-membrane, and possibly by an active transport of phosphatidyl-serine[5, 31, 
32]. These reactions result in loss of the physiological asymmetry of the membrane and the 
expression of phosphatidyl-serine on the outer leaflet. Once these events have taken place, 
vesicles are shed by budding from the cell-membrane. We expected therefore ectosomes to 
express phosphatidyl-serine and could demonstrate it by the binding of AnV. However, 
normal cells can restore this asymmetry over time[14], which was not the case for ectosomes 
(data not shown). This may reflect insufficient flipase-activity to restore the asymmetry owing 
to an insufficient amount of the enzyme and/or the absence of ADP/ATP-regeneration within 
ectosomes. Phosphatidyl-serine exposed on different types of micro-vesicles/ectosomes, 
including those derived from platelets, monocytes and endothelial cells, mediates 
procoagulant activities by recruiting coagulation factors[5, 20, 33-37]. Similar procoagulant 
properties have been attributed to PMN-derived ectosomes[38]. 
 
The second ectosomal protein identified by 2-DE/protein sequencing was annexin III. 
Annexin III is mainly expressed in PMNs. In resting PMNs it is associated with cytoplasmic 
granules, but translocates to the plasma membrane as soon as the cells get activated[39]. It is 
known to bind indiscriminately to membrane surface in a calcium dependent manner. Thus, it 
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is very likely that annexin III associates to forming ectosomes at the time of PMN-activation. 
The physiological role(s) of this protein are hitherto still largely unknown. However, annexin 
III has been proposed to mediate vesicle-fusion in secretory cells and might be involved in 
exocytosis. It might therefore play an active role in the process of ectocytosis as well. 
We have previously shown by co-immunoprecipitation, that CR1-bearing ectosomes co-
express HLA-I, CD46, CD55 and CD59, while CR1-bearing ectosomes did not co-
immunoprecipitate with detectable amounts of CD14[10]. FACScan-based analysis confirmed 
these findings, adding evidence for a specific ectosomal protein expression, not simply 
corresponding to protein expression on the PMN cell-surface membrane (absence of CD14 
but also of CD32 and CD87). The selection for ectosomal protein expression did not segregate 
between transmembrane- (TM-) and GPI-anchored proteins since both types of molecules 
were present (e.g. CR1TM, CD55GPI), respectively absent (e.g. CD14TM, CD32GPI) on 
ectosomes. However our technique did not allow us to define whether some of the molecule 
were enriched in the ectosomes as compared with the PMN-membrane. Such enrichment has 
been described on ectosomes released by erythrocytes for GPI-anchored proteins, but 
interestingly for CR1 as well[40]. Taken together these data would suggest that at the time of 
ectocytosis the shuffling of the membrane proteins follows rules, which are not specifically 
dependent on GPI anchoring.  
 
Upon activation, PMNs are known to shed very efficiently L-selectin (CD62L), as well as 
CD11b[41-46], CR1[47] and many other molecules[48-50]. Interestingly, ectosomes were 
found to express some of these molecules. Thus, early during activation PMNs release a set of 
cell-surface molecules by proteolytic cleavage but also by ectocytosis, indicating that both 
processes take place in an orchestrated manner. Shedding of cell surface molecules is thought 
to be a means for a rapid adaptation of the cellular phenotype[49]. For instance shedding of L-
selectin (CD62L) is known to be important during extravasation of PMNs in the transition 
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from a rolling phenotype to firm endothelial adhesion[51, 52]. In this respect, ectocytosis 
might be viewed as an additional efficient mechanism to modify the PMN cell-surface 
phenotype. On the other hand, the presence of CD62L on ectosomes might be essential for 
their adhesion properties. This observation suggests as well that enzymatic cleavage differs on 
the PMN cell-membrane and shed ectosomes. Smith et al. have shown recently that the 
susceptibility of erythrocytes to secretory phospholipase A2 after exposure to calcium 
ionophore was related to the specific properties of the lipid membrane, i.e. it was proportional 
to the increased order of membrane lipids[53]. One might speculate that, for ectosomes as 
well the enzymatic susceptibility of membrane molecules is related somehow to changes in 
the membrane lipid organisation. 
 
Among the most fascinating characteristics of PMN-derived ectosomes was the fact that they 
selectively combined molecules well segregated in resting PMNs, i.e. a series of adhesion 
molecules and many but not all enzymes stored within azurophilic granules. This unique 
grouping was related to different processes – selection of membrane proteins for adhesion 
molecules and specific binding of enzymes to the outer leaflet of the ectosome membrane. 
How enzymes are translocated to this site and the types of binding are ill defined. Taking 
advantage of MPO-deficient PMNs we studied the mechanism of MPO translocation to 
ectosomes. Ectosomes released from MPO-deficient PMNs were found to acquire MPO when 
exposed to S/N of degranulated normal PMNs (containing soluble MPO) or to purified MPO. 
This binding is not unique for ectosomes, since MPO is known to bind to resting PMNs as 
well[25]. Since the ectosomal membrane is negatively charged electrostatic interactions with 
cationic MPO are very likely to contribute to the binding. In contrast, PR3, another cationic 
enzyme present on PMN-derived ectosomes, has recently been shown not to rebind to PMN-
membranes[25]. PR3 instead translocates to the cell surface directly, exhibiting strong 
(possibly covalent) interactions with the membrane. Whether a fraction of MPO becomes 
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translocated in a similar manner cannot be excluded. Elastase, MPO and MMP-9 were in an 
enzymatically active form on whole, intact ectosomes. After disrupting the ectosomes by 
sonication there was no increase in the enzymatic activity of MMP-9 and elastase suggesting 
that this activity was limited to the outerside of the ectosome membranes with no storage 
compartment inside ectosomes. 
 
In addition to being present on PMN-derived ectosomes, active MMP-9 has been 
demonstrated on ectosomes derived from fibrosarcoma, breast carcinoma cells as well as 
endothelial cells[22, 23, 54]. PMNs store MMP-9 in three different pro-forms: monomers of 
92 kDa, dimers of 220 kDa and MMP-9/lipocalin heterodimers of about 130 kDa[55]. All 
forms are released upon PMN-activation and we found all storage-forms on the surface of 
ectosomes. Subsequent activation of MMP-9 is tightly controlled by ubiquitous tissue 
inhibitor of matrix-metalloproteinase-1 (TIMP-1)[56, 57]. Ectosomal MMP-9 might therefore 
become fully active thanks to elastase, which is known to inactivate TIMP-1[58]. Distinct 
ectosomal sets of molecules may locally shift the balance between inhibitory and activatory 
molecules, thereby allowing specific enzymes to escape inhibition. Besides acting on 
molecules in their microenvironment, ectosomal enzymes might also act on proteins 
expressed on the same ectosomes. This might explain the absence on ectosomes of certain 
proteins sensitive to proteolytic cleavage [e.g. CD14, uPAR (CD87)][59-61]. CD14 for 
instance has been shown to be sensitive to proteolytic cleavage by cathepsin G[59]. Cathepsin 
G is released at the time of PMN-activation; whether it is present on the surface of ectosomes 
is yet unknown. However, both soluble and ectosome-bound cathepsin G might cleave off 
CD14 from the surface of ectosomes. 
 
The overall cleavage process would however be very selective, since other molecules such as 
L-selectin, although shed from PMNs, are not cleaved from the surface of ectosomes. Uniting 
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adhesion molecules with antimicrobial enzymes (MPO, PR3 and/or elastase)[62-64] or 
matrix-degrading enzymes (elastase, PR3 and/or MMP-9)[63, 65-68] may target “effector” 
molecules to specific locations. This might be beneficial, e.g. by focusing antimicrobial 
activity on opsonised bacteria, but also contribute to local tissue destruction or cell activation. 
 
The expression on ectosomes of negatively charged lipids (such as phosphatidyl-serine) as 
well as different adhesion molecules suggested that they might be able to specifically bind to 
cells. Indeed ectosomes selectively and specifically bound HUVEC and THP-1 cells with high 
affinity/avidity, and not to erythrocytes. Many receptor(s) or molecule(s) of ectosomes may 
be involved in this binding, including L-selectin, and phosphatidyl-serine[69-72]. 
Interestingly, the addition of annexinV did not decrease or even block the binding of 
ectosomes to THP-1 cells (data not shown). We believe that the binding of ectosome to 
selective cell types might not occur through just one type of molecular interaction; blockade 
of one mechanism might be compensated by several others. Importantly, cytochalasin D did 
not prevent THP-1 cells to become fluorescent in our assays (data not shown), confirming that 
our experimental conditions tested binding. Longer incubation times might allow 
phagocytosis of ectosomes to occur. Whether phagocytosis of ectosomes induces a pro-
inflammatory or anti-inflammatory state in monocytes remains an intriguing question, 
particularly when one considers that ectosomes may have some similarities with apoptotic 
bodies which are under physiological circumstances cleared without producing harm[73-76]. 
C1q has been shown to bind to the surface blebs of apoptotic cells, a binding which occurs via 
the globular heads of C1q[77]. Recent evidence suggests that the binding of C1q is important 
for the non-phlogistic clearance of apoptotic cells, thus preventing the development of 
autoimmunity against the many newly expressed antigens on apoptotic cells. Interestingly, 
C1q-deficiency individuals develop an autoimmune disease, which is very similar to systemic 
lupus erythematosus[78]. Here we showed that ectosomes bind C1q from serum similarly to 
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apoptotic cells. We have no evidence yet to suggest that the binding and clearance of 
ectosomes is regulated by C1q binding, but from the foregoing this possibility remains open. 
In summary, many of the biochemical characteristics of ectosomes of PMNs have been 
analysed in the present work. The observations made open new avenues in the way we think 
about the biological role of the released ectosomes. In addition, the clear definition of 
ectosomes, as detailed here, could serve as a basis for a unified terminology, which would 
replace, the multiple names used until now (microparticles, microvesicles, etc.). This would 
also underline the difference between ectosomes and exosomes which are formed by another 
process and might have very different functions. 
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Part II: 
 
Activated Polymorphonuclear Neutrophils disseminate Anti-inflammatory 
Microparticles by Ectocytosis 
 
Abstract 
Upon activation, human neutrophils release microparticles, called ectosomes, directly from 
the cell surface membrane. Microparticles from platelets, endothelial cells and monocytes 
were reported to support coagulation or to modulate vascular homeostasis by activating 
monocytes as well as endothelial cells. We find that neutrophil ectosomes have no pro-
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inflammatory activity on human macrophages as assessed by the release of IL-8 and TNFα. 
On the contrary, ectosomes increase the release of TGFβ1, suggesting that ectosomes 
downmodulate cellular activation in macrophages. PMN ectosomes are able to block 
macrophages’ inflammatory response to zymosan and LPS, an effect that is partially mediated 
by the early-phase TGFβ1 secretion. Ectosome-cell contact was sufficient for their 
immunomodulatory function as shown by blocking phagocytosis with cytochalasin D. Thus, 
neutrophils release potent anti-inflammatory effectors, in the form of ectosomes, at the 
earliest stage of inflammation, already providing a drive to its resolution. 
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Introduction 
Polymorphonuclear neutrophils (PMN) constitute the bulk of the leukocytes found in our 
blood. PMN ingest and eventually kill invading pathogens by means of potent antimicrobial 
agents released during the process of degranulation. As this microbicidal weaponry largely 
lacks specificity, it can lead to severe tissue damage if not controlled or secluded adequately 
from surrounding tissue1. At the time of degranulation, activated PMN release small 
microvesicles directly from the cell surface membrane. Many eukaryotic cells, including 
tumors cells, release vesicles by ectocytosis (ectosomes), either spontaneously, or in response 
to various stimuli2-14. Data on the function(s) of ectosomes have accumulated recently6,7,9,11,15-
17. So far, ectosomes have been associated with pro-coagulant and pro–inflammatory effects. 
Ectosomes derived from endothelial cells have been described to induce pro-coagulant 
activity in monocytic cells18, whereas ectosomes from platelets and monocytes were shown to 
directly promote hemostasis and induce inflammation by activating endothelial cells9,11. 
MacKenzie et al. described monocyte-derived ectosomes as being important pro-
inflammatory agents by mediating the rapid secretion of IL-1β6.  
We recently described characteristics and molecular properties of ectosomes released by 
human PMN19,20. Here we show that PMN derived ectosomes, unexpectedly, feature 
immunosuppressive/anti-inflammatory functions. Challenging a linear model of induction and 
resolution of inflammation, our data suggest a more complex balance of pro- and anti-
inflammatory events initiated in a parallel manner. 
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Material and Methods 
Antibodies and Reagents 
Zymosan A from Saccharomyces cerevisiae and cytochalasin D were from Sigma (St-Louis, 
MO) and LPS was from Calbiochem (La Jolla, CA). Human TGFβ1 Duoset® ELISA 
development system as well as neutralizing monoclonal mouse anti-human-TGFβ antibodies 
(αTGF-Abs) were from R&D Systems (Minneapolis, MN). OptEIA ELISA kits for IL-8, IL-
10 and TNFα were from Becton Dickinson (San Diego, CA). 
 
Isolation and stimulation of PMN , collection of ectosomes 
PMN were isolated from fresh buffy coats according to the technique described previously19. 
Briefly, a fresh buffy coat was diluted 1/1 (v/v) with PBS-EDTA (2 mM), mixed gently with 
0.25 vol of 4% Dextran T500 (Amersham Pharmacia Biotech, Dübendorf, Switzerland), and 
left for 30 minutes for erythrocyte sedimentation. The leukocyte-rich supernatant was 
aspirated and centrifuged for 10 minutes at 200g. The pellet was resuspended in 9 mL of 
ultrapure water to lyze erythrocytes. Isotonicity was restored by addition of 3 mL of KCl (0.6 
M) and 40 mL of NaCl (0.15 M). Cells were then centrifuged 10 minutes at 350g, and 
resuspended in 20 mL of PBS-EDTA. This suspension was layered over 20 mL of Ficoll-
Hypaque (Sigma, St-Louis, MO) and centrifuged for 30 minutes at 350g. The PMN-rich pellet 
was recovered and washed twice in PBS-EDTA. All manipulations were performed at 4°C, 
thus minimizing PMN-activation. 
For stimulation, PMN (107 cells/mL) were diluted 1/1 (v/v) in pre-warmed (37°C) RPMI 1640 
(Life Technologies, Basel, Switzerland) with 1 µM fMLP (final concentration; Sigma, St-
Louis, MO), and incubated for 20 minutes at 37°C. PMN were removed by centrifugation 
(4000g at 4°C). The ectosomes contained in the supernatant were concentrated with 
Centriprep® centrifugal filter devices (10,000 MW cut-off, Millipore Corporation Bedford, 
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MA) and stored in aliquots at -80°C until use. The load of ectosomes was estimated in units 
(i.e. one unit of ectosomes corresponding to the ectosomes released by 107 PMN). 
 
Isolation and culture of human monocyte derived macrophages (HMDM) 
Monocytes were isolated from fresh buffy coats as previously described21. Briefly, a buffy 
coat was diluted 1/1 (v/v) with HBSS, layered over Ficoll-Hypaque (Sigma, St-Louis, MO) 
and centrifuged for 30 minutes at 350g. Monocytes were recovered, washed twice in HBSS 
and layered over a Percoll gradient. Percoll was prepared mixing 1 volume NaCl 1.5 M with 9 
volumes of Percoll (Sigma, St-Louis, MO). The Percoll gradient was done mixing 1.5:1 (v/v) 
isosmotic Percoll with PBS/Citrate (NaH2PO4 1.49 mM; Na2HPO4 9.15 mM; NaCl 139.97 
mM; C6H5Na3O7 .2H2O 13mM; pH 7.2). Isolated monocytes were resuspended at 2 x 106 
cells/mL in DMEM supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin and 2 
mM L-glutamine (DMEM+). Monocytes were then allowed to adhere for one hour at 37°C on 
culture plates. Adherent monocytes were washed 3 times with prewarmed DMEM+ and 
finally incubated for 7 days in DMEM+ supplemented with 10% normal human serum 
(pooled from 40 healthy donors).  The culture was maintained in 5% CO2 at 37°C and the 
medium was changed at days 3 and 7. Macrophages were used between days 7 and 10. 
 
Activation of HMDM 
HMDM were washed several times with pre-warmed DMEM+ without serum. Subsequently, 
each well was filled with 200 µL (final volume) fresh DMEM+ without serum. Zymosan (5 
µg/mL final concentration), LPS (10 ng/mL final concentration) and/or ectosomes were added 
and supernatants were collected 24 hours later (if not stated otherwise). For kinetic 
experiments, supernatants were collected at the time points 1, 2, 4, 8 and 24 hours. For some 
experiments, HMDM were pre-treated with 0.5 µM cytochalasin D in DMEM+ for 60 
minutes at 37°C prior to washes and incubation with zymosan and/or ectosomes. For the dose-
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dependent activity of ectosomes on activated HMDM, the highest dose of ectosomes used was 
equivalent to the amount released by 108 PMN. For all other assays, the amount of ectosomes 
were set to obtain good but not complete inhibition of HMDM activation. Assays were 
performed in triplicate. Presented results are representative of three independent experiments. 
Data represent mean ± standard deviation. 
 
Collection of supernatants and analysis of cytokines 
HMDM supernatants were collected, put on ice and spun for 10 minutes at 2,000 rpm at 4°C 
(Mikro 24-48R centrifuge from Hettich, Bäch, Switzerland) to remove cellular debris. Finally, 
supernatants were collected and stored at –80°C until use. Cytokine concentrations were 
determined by ELISA according to manufacturers’ instructions.  
 
Membrane labeling of ectosomes 
An amphiphilic cell linker dye kit (PKH67, Sigma, St-Louis, MO) was used, following the 
labeling procedure provided by the manufacturer. Briefly, ectosomes resuspended in 200 µL 
Diluent C were incubated with 200 µL diluent C/dye solution (dye diluted 1/200) for a minute 
at room temperature, with gentle shaking. 1 mL RPMI 1640 (without phenol red) was added 
to stop the reaction. Labeled ectosomes were separated from the remaining unbound dye by 
ultracentrifugation (45 minutes, 160,000g/4°C) and washed with 0.9% NaCl. 
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Confocal fluorescence microscopy 
HMDM were generated as described above on 8-well culture slides (Falcon / Becton 
Dickinson, NJ, USA). After 7 to 10 days of culture, macrophages were washed several times 
with serum free DMEM+ medium and incubated with fluorescently labeled ectosomes (as 
described above). Analysis was performed on a Axiovert Confocal Laser Scanning 
Microscope (LSM 510) from Zeiss AG (Feldbach, Switzerland). 
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Results 
PMN ectosomes do not induce pro-inflammatory activity in macrophages 
To investigate whether ectosomes derived from neutrophils have a similar pro-inflammatory 
effect as has been reported for ectosomes of different cellular origin, we co-incubated PMN 
ectosomes with human monocyte-derived macrophages (HMDM) for 24 hours. Supernatants 
were analyzed for IL-8, TNFα, IL-10 and TGFβ1. No stimulating or activating effect of 
ectosomes on macrophages was observed (Fig 1A), whereas zymosan and LPS induced the 
release of IL-8, TNFα and IL-10. Surprisingly, ectosomes increased the release of the anti-
inflammatory cytokine TGFβ1.  
 
PMN ectosomes downregulate the inflammatory response of HMDM to zymosan 
Through co-incubation of zymosan or LPS with ectosomes we assessed whether ectosomes, 
besides being intrinsically non-inflammatory, alter the response of HMDM to pro-
inflammatory stimuli. Zymosan and LPS induced the release of IL-8, IL-10 and TNFα, but 
not of TGFβ1. In presence of zymosan, ectosomes significantly downregulated the release of 
IL-8 and IL-10, completely blocked the secretion of TNFα but increased the release of 
TGFβ1. Ectosomes were best at counteracting the pro-inflammatory response to zymosan, 
although with regards to TNFα and TGFβ1, the response to ectosomes was very similar. 
Interestingly, the overall effect of ectosomes on activated macrophages could not be blocked 
by pre-incubating ectosomes in normal human serum (i.e. in the presence of serum proteins) 
for 30 minutes at 37˚C. Furthermore, as shown in figure 1C, ectosome-induced 
downregulation of IL-8, IL-10, TNFα secretion and induction of the secretion of TGFβ1 was 
dose-dependent. In the highest amount used in our assay, ectosomes completely blocked the 
inflammatory response of HMDM. Noteworthy, the release of cytokines by macrophages and 
its inhibition/promotion by ectosomes after activation with stimuli has an intrinsic variability 
due to nearly each experiment being carried out with cells and ectosomes isolated from 
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different blood donors. This variability is particularly reflected in figure 1A, B and C by the 
different background releases of TGFβ1 in resting macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0                 1                 10 
0                 1                 10 Ø             ectosomes       zymosan            LPS 
ectosomes (units) 
0                 1                 10 
ectosomes (units) 
Ø           zymosan     zymosan       LPS           LPS 
                               +ectosomes                 +ectosomes 
Ø             ectosomes       zymosan            LPS 
Ø             ectosomes       zymosan            LPS 
0 100 
200 300 
400 500 
600 700 
800 900 
Ø           zymosan     zymosan       LPS           LPS 
                               +ectosomes                 +ectosomes 
800 
700 
600 
500 
400 
300 
200 
100 
0 
+ zymosan
 ectosomes (units) 
600 
500 
400 
300 
200
100
0
250
200
150
100
0 
50
0 
50 
100 
150 
200 
250 
300
B)  
+ zymosan 
600 
500 
400 
200
100
700 
300 
0 
+ zymosan
30
C)
0 
250 
200 
150 
100 
50 
+ zymosan
2 3 40                 1                 10 
ectosomes (units)  
180 
Ø           zymosan     zymosan       LPS           LPS 
                               +ectosomes                 +ectosomes 
0 
160 
140 
120 
100 
80 
60 
20 
0 
700
Ø           zymosan     zymosan       LPS           LPS 
                               +ectosomes                 +ectosomes 
Ø             ectosomes       zymosan            LPS 
0 
50
900 
800
700 
600 
500
400
300 
200 
100 
0 
300
A) 
150
200
250
IL-8 
in  
pg/mL 
100
50
0
TNFα 
in  
pg/mL 
40 
Ø 
Ø 
Ø 
Ø 
250
IL-10 
in  
pg/mL 
200
150
100
400
350
150
200
2
3TGFβ1 
in  
pg/mL 
00
50
100
50
0
 
 
Figure 1: PMN ectosomes are not pro- but anti-inflammatory 
A) HMDM were incubated with medium alone (Ø), with medium supplemented with 
ectosomes (1 unit), zymosan or LPS for 24 hours. Supernatants were analyzed for IL-8, IL-10, 
TNFα and TGFβ1. B) HMDM were incubated with medium alone (Ø), with medium 
supplemented with zymosan or LPS, with or without ectosomes for 24 hours. Supernatants 
were analyzed for IL-8, IL-10, TNFα and TGFβ1. C) HMDM were incubated with medium 
alone (Ø), with medium supplemented with zymosan with (1 or 10 units) or without 
ectosomes for 24 hours. Supernatants were analyzed for IL-8, IL-10, TNFα and TGFβ1. 
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Kinetic response of HMDM to ectosomes and/or zymosan 
Next, we assessed whether the diminished release of pro-inflammatory cytokines in response 
to ectosomes was due to a true blockade of intra-cellular pro-inflammatory pathways or rather 
a delayed response. We therefore investigated the time dependent effect of ectosomes on the 
cytokine secretion of both, resting and zymosan-stimulated HMDM (Fig. 2). Ectosomes 
induced a rapid and sustained release of TGFβ1 in resting and stimulated HMDM. In the 
presence of zymosan, ectosomes had a profound anti-inflammatory activity on HMDM 
detectable at all time points. The kinetics of IL-8, IL-10 and TNFα release by activated 
macrophages were similar in the absence and presence of ectosomes, although in the latter the 
amplitudes were significantly decreased. This indicates that the immunosuppressive activity 
of ectosomes is not due to a delay in the response of macrophages to pro-inflammatory 
stimuli, but rather to an active suppression of cell activation. 
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Figure 2: Kinetic of cytokine release by 
HMDM dependent on zymosan and/or 
ectosomes 
 
HMDM were incubated with medium 
alone (Ø) with or without ectosomes (1 
unit) and with medium supplemented 
with zymosan with or without ectosomes 
for up to 24 hours. Supernatants were 
harvested after 1, 2, 4, 8 and 24 hours and 
analyzed for IL-8, IL-10, TNFα and 
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Ectosomes are phagocytozed by HMDM 
We previously observed that ectosomes bind specifically to macrophage-like cells 
differentiated from THP-1 cells 20. Here, we addressed the question whether ectosomes are 
phagocytozed by macrophages and whether the process of phagocytosis is involved in the 
immunosuppressive function of ectosome on macrophages.  
We performed confocal fluorescence microscopy of HMDM after incubation with 
fluorescently labeled ectosomes. As shown, ectosomes do not only bind to macrophages but 
are internalised as well (Fig. 3A). We performed assays with HMDM that were kept in 
medium alone and others that were pre-incubated with cytochalasin D (cytD), a potent 
inhibitor of phagocytosis. In absence of cytD, the vast majority of macrophages have 
phagocytozed ectosomes after 30 minutes, as reflected by the intense fluorescent staining of 
most of the cells (i). In contrast, cytD pre-incubated macrophages show a marked decrease in 
fluorescence and hence uptake of ectosomes (Panel iii). At higher magnification, cells that 
have ingested ectosomes accumulated fluorescence in intracellular compartments (Panel ii), 
which were not visible after pre-treatment with cytD (Panel iv). 
We then used again cytD to determine whether phagocytosis is required for ectosomes to 
fulfil their anti-inflammatory effects on macrophages. Since CytD significantly influenced the 
TNFα response of HMDM in the presence or absence of zymosan, we excluded TNFα results 
from our analysis. As shown in the panels B-C (Fig. 3), inhibiting ectosome-phagocytosis 
could not block the anti-inflammatory effect of ectosomes on HMDM. 
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Figure 3: Confocal microscopy of phagocytosis and phagocytosis independent anti-
inflammatory activity of ectosomes 
A) HMDM were incubated with fluorescently labeled ectosomes for 30 minutes, fixed and 
analyzed by confocal laser microscopy (i-ii). Alternatively, macrophages were pre-incubated 
cytochalasin D (cytD) prior to the addition of ectosomes (iii-iv). B)-D) HMDM were 
incubated with medium alone or with medium supplemented with zymosan for 24 hours. 
Alternatively, ectosomes (1 unit) were added to the incubation medium with or without pre-
incubating the macrophages with cytD. 
 
 
Effect of neutralizing anti-TGFβ antibodies on anti-inflammatory activity of ectosomes 
In order to understand how ectosomes exert their immunosuppressive activity on 
macrophages. The kinetic data presented earlier suggested that the first event occurring during 
co-incubation of macrophages with zymosan and ectosomes is the ectosome-induced release 
of TGFβ1. We tested whether the rapid rise in local TGFβ1 concentration as shown in Fig. 2 
is responsible for the subsequent downregulation of IL-8, IL-10 and/or TNFα release in 
activated macrophages. As shown in Fig. 4, neutralizing αTGF-Abs had a lowering effect on 
the anti-inflammatory activity of ectosomes. This effect ranged from complete blockade of 
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ectosome-function with respect to downregulation of IL-8, to only partial inhibition of the 
downregulatory activity of ectosomes in the case of IL-10 and TNFα. 
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Figure 4: Effect of neutralizing anti-human-TGFβ antibodies on anti-inflammatory 
activity of ectosomes 
HMDM were incubated with medium alone (Ø), medium with ectosomes (1 unit) or with 
medium supplemented with zymosan for 24 hours. Alternatively, zymosan-medium was 
supplemented with ectosomes alone (no antibodies) or ectosomes with 5mg/mL or 50mg/mL 
of αTGFβ-Abs. Supernatants were analyzed for IL-8, IL-10 and TNFα. 
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Discussion 
This study associates ectosomes to an active role in the resolution of inflammation. This 
function of PMN derived ectosomes is striking, as it counterbalances the immediate pro-
inflammatory effects of many of the substances released by activated PMN. Our data 
challenge the sequential model of induction and resolution of inflammation, and suggest a 
balanced occurrence of pro- and anti-inflammatory events, orchestrated in a parallel manner.  
 
Ectosomes share with apoptotic bodies the expression of phosphatidylserine (PS) in the outer 
membrane leaflet. Similarly to apoptotic cells, the uptake of ectosomes by macrophages might 
depend on the exposure of PS in the outer membrane leaflet22. In addition, and in analogy to 
apoptotic cells, the uptake of ectosomes by macrophages is accompanied by a reprogramming 
of the macrophages, featuring an anti-inflammatory phenotype, and this biological effect does 
not require phagocytosis.    
 
The receptor for PS has recently been shown to be directly involved in the resolution of 
inflammation by inducing the release of TGFβ1 in macrophages that have ingested apoptotic 
cells23,24. Here, we show that ectosomes, in further analogy to apoptotic bodies, promote the 
dose-dependent release of TGFβ1 in activated as well as resting macrophages, and an 
inhibition of IL-8, IL-10 and TNFα secretion in activated macrophages. Anti-TGFβ-Abs 
counteracted the inhibition of IL-8 release induced by ectosomes suggesting that IL-8 release 
is regulated by autocrine and/or paracrine action of TGFβ1; similar observation has been 
made with apoptotic cells. However, and in distinction to what happened with apoptotic cells, 
αTGF-Abs had little effect on the inhibition of IL-10 and TNFα release25. 
It thus seems likely that ectosomes and apoptotic cells engage distinct but overlapping but 
different pools of receptors on the surface of macrophages. 
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 Our report follows a series of papers on functions of ectosomes, alternatively called 
microparticles or microvesicles6,7,9,11,15,16. In most cases, ectosomes were described as having 
pro-inflammatory properties. Plasma counts for microparticles of various cellular origin were 
analyzed in a number of pathophysiological situations and such microparticles were found to 
induce endothelial dysfunction8,14,26. This contrasts our data for PMN, suggesting that the 
cellular origin of ectosomes as well as the target cells may determine their biological 
response. This fact is illustrated by recent work of Mesri et al. that described activating 
properties of PMN microparticles on endothelial cells15,27. However, the microparticles used 
in these experiments were isolated after several hours. Microparticles were not selected for 
early-released ectosomes, as used in this work, and may have contained early apoptotic 
components and microparticle-membranes modified by hydrolysis, conferring to them very 
different properties28. 
 
In conclusion, ectocytosis of PMN early during activation might produce microparticles with 
immunosuppressive function and create an immediate counterweight for simultaneously 
unfolding pro-inflammatory mechanisms. Fascinating is that PMN, best known for their 
powerful and immediate phlogistic properties, release particles/ectosomes which seem to 
downregulate the inflammatory activity of the second wave of cells (macrophages) that will 
be attracted to the site of initial damage. 
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 Part III: 
 
Microparticles released by Human Neutrophils adhere to Erythrocytes in the 
presence of Complement 
 
Abstract 
The release of cell surface-derived microparticles, or ectosomes, has now been described for 
many different cell types. We reported previously on the binding of the first component of the 
classical pathway of complement, C1q, to the surface of ectosomes released by human 
neutrophils. Here, we show that the binding of C1q induces the activation and deposition of 
complement on the surface of ectosomes through the classical pathway. Furthermore, the 
opsonization of ectosomes by complement mediated their immune adherence to erythrocytes 
through complement receptor 1. Taken together, our data suggest an important role for 
complement and erythrocytes in the sequestration, and possibly clearance, of blood-borne 
microparticles stemming from PMN but potentially from other blood cells as well. 
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Introduction 
Whilst studying polymorphonuclear leukocytes (PMN), Stein and Luzio observed the release 
of vesicles that pinched off directly from the cell membrane when PMN were challenged with 
sublytic amounts of complement by a mechanism they termed ectocytosis1.  A similar 
phenomenon occurs in many different cell types in response to a variety of stimuli. 
Ectocytosis occurs immediately after stimulation and is therefore timely and mechanistically 
well distinct from apoptosis. Beside PMN, endothelial cells, monocytes, platelets and 
erythrocytes are known to release microparticles by ectocytosis in vitro and in vivo2-6. For 
clarity, we will refer to “ectosomes” when describing such microparticles. A number of 
different functions have been attributed to ectosomes. They allow the rapid shedding of IL-1β, 
released by activated THP-1 cells7. Ectosomes can serve as intercellular protein-carriers for 
tissue factor and the chemokine receptor CCR58,9. As far as platelet ectosomes are concerned, 
their most prominent feature is a pronounced procoagulant activity.  
 
Microparticles of diverse cellular origin -probably mainly ectosomes- are present in blood of 
normal individuals10. Quantitative and qualitative changes, i.e. increased numbers of 
microparticles derived from different origins, were described in many diseases including 
sepsis11, severe trauma12, paroxysmal nocturnal hemoglobinuria13, diabetes14,15, acute 
coronary syndromes16 and lupus2. Whether ectosomes of PMN are deleterious is unknown, 
but the level of blood microparticles of PMN correlated with the severity of sepsis11. 
However, even in sepsis the real number of these microparticles is surprisingly low, when 
compared to the high numbers released by activated PMN in vitro.   
 
Here we present evidence that most ectosomes of PMN might not be free in circulation, as 
assumed until now. Indeed, ectosomes released by human PMN activate the classical pathway 
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of complement and fix C4 and C3 fragments. These opsonized ectosomes bind in turn to 
erythrocytes via the complement receptor 1 (CD35/CR1). 
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Material and Methods 
Antibodies and Reagents 
Anti-human-C3d and -C4d antibodies (Abs) were from Quidel (Santa Clara, CA) and human 
C1q was from Calbiochen (San Diego, CA). Phycoerythrin coupled anti-glycophorin A and 
goat anti-mouse-Ig Abs were from Pharmingen (San Diego, CA) and Southern Biotechnology 
Associates Inc. (Birmingham, AL), respectively. Lepirudin (Refludan®) was from Hoechst 
(Zürich, Switzerland). 
 
Isolation and stimulation of PMN 
PMN were isolated from buffy coats as described previously17. PMN were resuspended in 
RPMI 1640 with 1 µM fMLP and incubated for 20 minutes at 37°C. PMN were removed by 
centrifugation. The supernatant was concentrated with centrifugal filter devices (Millipore, 
Bedford, MA) and stored in aliquots at -80°C until use. 
 
Membrane labeling of ectosomes 
An amphiphilic dye kit (PKH67, Sigma, St-Louis, MO) was used, following the labeling 
procedure provided by the manufacturer. Labeled ectosomes were separated from the 
remaining unbound dye by ultracentrifugation and washed with 0.9% NaCl. 
 
Complement activation assays on ectosomes by Fluorescence Activated Cell Scanning 
(FACScan) 
Ectosomes were isolated from concentrated PMN supernatant by ultracentrifugation. 
Ectosomes were resuspended in complement fixation diluent (CFD) supplemented with 10% 
heat-inactivated normal human serum (HI-NHS), normal human serum (NHS), C1q-deficient 
or C2-deficient serum and incubated for 30 minutes at 37°C. Ectosomes were then washed 
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with CFD and incubated with primary Abs. Detection was performed with goat anti-mouse-
Ig-PE Abs. 
 
Fluorescence microscopy and FACScan of erythrocytes / whole blood 
Ectosomes were fluorescently labeled as mentioned above. Fresh erythrocytes were isolated 
from lepirudin anticoagulated blood, washed several times with RPMI 1640 and incubated 
with ectosomes in medium supplemented with 10% autologous lepirudin plasma for 30 
minutes at 37ºC. Erythrocytes were washed gently several times with PBS and analyzed. 
Alternatively, reconstituted whole blood was used. The reconstitution of whole blood was 
performed isolating all blood cells from EDTA anticoagulated blood and adding autologous 
serum to regain initial blood volume.
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Results and discussion 
Ectosomes bind C1q, the first component of the complement system17. We investigated 
whether this binding was followed by complement activation and deposition on the surface of 
ectosomes. As shown in Figure 1A panel (a), both C4 and C3 fragments were fixed onto 
ectosomes after exposure to 10% normal human serum. This complement activation was 
driven by the classical pathway as shown in a C2 deficient serum, in which C4 fragment 
binding took place, but which was not followed by C3 fragment fixation (panel (b)). This 
result indicated as well, that the alternative pathway was not capable by itself to opsonize the 
ectosomes with C3. In C1q deficient serum there was no complement fixation (panel (c)). 
Since this C1q deficient serum has been shown to have a functional mannan-binding pathway 
(kindly measured by J. Jensenius), we concluded that the initial deposition C1q was an 
absolute requirement for further complement activation. Finally, the classical pathway 
deposition of C3 was followed by membrane attack complex-formation on the surface of 
ectosomes (panel (d)).  
 
Next, we tested whether complement deposited on ectosomes acts as an opsonizing agent, 
ultimately targeting ectosomes to erythrocytes, known to bear clusters of CR1 and function as 
carrier for complement-opsonized viruses, bacteria and immune complexes18-20. We 
performed FACScan experiments using fluorescent ectosomes and purified human 
erythrocytes, which were incubated in either lepirudin plasma (LP), LP-EDTA, C1q- or C2-
deficient serum. We then assessed the fraction of erythrocytes having bound ectosomes. As 
shown in Figure 1B, non-opsonized ectosomes had only a small binding capacity to 
erythrocytes, whereas the number of erythrocytes bearing ectosomes increased almost 4-fold 
in the presence of 10% autologous LP. When EDTA was added to the plasma or when C1q-, 
or C2-deficient serum were used instead, the binding efficiency of ectosomes was decreased 
back to non-specific levels. C1q alone was unable to mediate binding even in supra-
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physiological concentrations (200µg/mL). These results indicate that the immune adherence 
of ectosomes is complement dependent, requires C3 fragment binding, and that C1q in 
plasma, which can directly bind to CR121, does not significantly support this binding. In this 
respect ectosomes appear to have similar properties to immune complexes22.  
Figure 1: Activation and deposition of
complement on the surface of ectosomes /
complement dependence and fluorescence
microscopy of the binding of ectosomes to
purified erythrocytes. 
A) FACScan histogram plots showing the
deposition of C3- and C4-fragments and
C5b-9 complexes on ectosomes. a)-c): the
violet, green and red curves represent the
fluorescences of ectosomes incubated with
isotype control mouse(m)-IgG1 Abs,
monoclonal m-anti-C3d Abs and monoclonal
m-anti-C4d Abs, respectively, detected with
goat anti-m-Ig-PE Abs. The experiments
were performed in CFD supplemented with
10% NHS, C2- and C1q-deficient serum,
respectively. Panel d) represents the
deposition of MAC on ectosomes after
incubation in NHS (red curve) or HI-NHS
(green). B) Percentage of purified human
(hE) or sheep (sE) erythrocytes that bound
fluorescently labeled ectosomes (ectos*) in
the presence of 10% autologous lepirudin
plasma, plasma supplemented with EDTA,
C1q- or C2-deficient serum or buffer
supplemented with C1q. C) Erythrocytes
were incubated with fluorescent ectosomes
in the presence of 10% plasma, washed and
analyzed by fluorescence microscopy. 
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Finally, the immune adherence of ectosomes was CR1 dependent, since it was completely 
abrogated by monoclonal anti-CR1 Abs (3D9), known to interfere with the C3b binding site 
on CR1, and absent on sheep erythrocytes, which lack CR1 (Fig. 1B). The same data were 
obtained by direct microscopy. The fine fluorescent ectosomes were seen attached on the 
surface of erythrocytes only in the presence of an intact classical pathway and normal human 
erythrocytes as illustrated in Figure 1C. 
 
We then investigated the immune adherence of ectosomes in more physiological conditions, 
using fluorescent ectosomes and reconstituted whole blood. Anti-gpA Abs (αgpA-PE) were 
used to label erythrocytes. As shown in Figure 2, we could detect significant amounts of 
double positive events after incubation of reconstituted blood with ectosomes (6% of 
erythrocytes; > 90% of ectosome-positive events) (panel (c)).  
 
 
 
 
 
 
 
 
Figure 2: Binding of ectosomes to erythrocytes in whole blood. 
FACScan dot plots showing the binding of ectosomes to αgpA-PE labeled erythrocytes (Ery) 
in reconstituted whole blood. a) Control fluorescence of whole blood in the absence of 
ectosomes. b) αgpA-PE labeled whole blood in the absence of ectosomes. c) αgpA-PE 
labeled whole blood incubated with fluorescent ectosomes. d) αgpA-PE labeled whole blood 
incubated with fluorescent ectosomes in the presence of EDTA. 
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We performed similar experiments adding EDTA to the reconstituted blood. As shown in 
panel (d), the counts of erythrocytes having bound ectosomes were reduced to 1.5%. 
Noteworthy, leukocytes did not bind significant amounts of ectosomes, probably because 
under physiological conditions the clustered distribution of CR1 on erythrocytes provided a 
significant binding advantage23. Taken together, these data suggest that the complement 
dependent immune adherence of ectosomes is likely to occur in vivo, i.e. in circulation, as 
well.  
 
In conclusion, we suggest that the complement dependent immune adherence of ectosomes is 
a mechanism by which ectosomes are secluded in the circulation and possibly cleared 
subsequently in liver and spleen similarly to immune complexes. Although we tested only 
PMN-derived ectosomes for complement activation and immune adherence, other blood-
borne microparticles might have similar complement activating properties. If this is the case, 
then erythrocytes may be considered as a buffer adsorbing microparticles, thus removing them 
from possible interactions with endothelial cells. The reduced number of CR1 on erythrocytes 
in SLE and other conditions might be detrimental for the physiological sequestration of 
microparticles. Finally the immune adherence of ectosomes should be taken into account 
when analyzing and interpreting quantitative and qualitative microparticle-counts in disease.  
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General Conclusion / Future perspectives 
Several conclusions can be drawn from the work presented here. First, human 
polymorphonuclear neutrophils (PMN)- derived ectosomes are released by a mechanism that 
selectively sorts cell-derived proteins into ectosome-membranes. This process, that remains to 
be fully unravelled, fits ectosomes with adhesion molecules and receptors, some of which 
might play a role in their binding affinities to phagocytic and endothelial cells, and active 
enzymes, including elastase, which might play a role in hemostasis. Second, PMN-ectosomes 
feature a marked anti-inflammatory activity when binding to human macrophages, a likely 
situation in inflamed tissue. It is tempting to assume that this function is mediated by 
phosphatidylserine, a negatively charged phospholipid confined to the inner membrane 
bilayer in healthy resting cells and presented in the outer layer on ectosomes; the reason being 
that this feature was associated to similar immunomodulatory activites observed for apoptotic 
cells1,2. Third and last, in contrast to the situation in tissue, the behaviour of ectosomes in 
blood was suggesting a somewhat different fate. Blood-borne ectosomes activate and bind 
complement, and are subsequently bound to erythrocytes, likely to mediate their clearance 
from the circulation, similarly to immune complexes. 
 
The mechanism of ectocytosis is far from being understood. One possible means to release 
membrane vesicles is the loss of membrane lipid asymmetry3-7. Membrane phospholipid 
asymmetry is controlled by several proteins or protein-complexes: an ATP-dependent 
aminophospholipid-specific translocase, an ATP-dependent nonspecific lipid floppase and a 
Ca2+-dependent non-specific lipid scramblase8. As the initial trigger, an increase in 
cytoplasmic Ca2+-concentrations positively and negatively controls scramblase- and 
translocase-activities, respectively, and thereby promotes the loss of membrane asymmetry. In 
addition, Ca2+-induced calpain activation favours vesicle formation and release of right-side 
oriented, phosphatidylserine exposing microparticles, corresponding to ectosomes9,10. The 
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collapse of membrane asymmetry is also facilitated by complement. Complement-induced 
release of microparticles exposing phosphatidylserine (PS) at their surface has been observed 
in endothelial cells, platelets and, as the first report describing and defining ectocytosis, in 
PMN11-13. 
 
It is unlikely that the breakdown of membrane lipid asymmetry is sufficient to induce 
ectocytosis. Many reports have suggested that structural proteins might be involved in the 
maintenance of lipid asymmetry and may thus modulate vesiculation14,15. The involvement of 
the cytoskeleton in ectocytosis is further suggested by the presence of filamentous actin in 
PMN-ectosomes, as shown in Part I. Recent data from Frasch et al. provide evidence for the 
selective enrichment of the phospholipid scramblase in detergent insoluble membrane regions 
(rafts) on the surface of fMLP-stimulated PMN16. Considering that rafts have been involved 
in the formation and the protein-sorting mechanism of exosomes it is conceivable that 
ectosomes could form preferentially at sites where specific membrane structure (rafts) 
colocalise with protein-complexes that mediate the collapse of membrane asymmetry.  
 
The understanding of the molecular mechanisms of ectocytosis would be of great interest to 
functionally compare ectosomes from different cellular origin. If the PS-expression on the 
surface of ectosomes is a common feature of ectosomes regardless of the cell-type they 
derived from, one would expect to observe overlapping functions. Indeed, as alluded to above, 
the anti-inflammatory activity of PMN-ectosomes described in Part II is likely to be 
dependent on PS. The function of ectosomes would then result from common, mainly 
structural, elements conferring them “basic” characteristics and cell-specific protein-patterns 
adding individual functional traits. The function of ectosomes might also be influenced by the 
site of their genesis. Indeed, ectosomes released from circulating or extravasated PMN might 
encounter a different environment. Whereas blood-borne PMN-ectosomes are enabled to 
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interact with massive amounts of serum proteins, including complement and components of 
the coagulation cascade, ectosomes released from extravasated PMN face a different situation 
in the extracellular space in tissue. Common features, like the expression of PS, might then 
adopt several functions. PS, as a negatively charged phospholipid, is known to be essential for 
hemostasis by acting as a docking site for coagulation components mediating thrombin 
formation17-20. PMN-ectosomes might therefore promote coagulation in the circulation, as has 
been described for platelet-ectosomes21. Active human neutrophil elastase present on the 
suface of PMN-ectosomes could play an additional procoagulant role in inactivating tissue 
factor inhibitor (O. Gasser, unpublished results, collaboration with Prof. Engelmann, 
Munich)22-24. 
It would be interesting to confirm and describe the procoagulant activity of PMN-ectosomes 
in circulation and to investigate whether PMN-ectosomes retain at the same time their anti-
inflammatory activity when released in blood, to rule out possible mutually exclusive 
mechanisms. Conceivably, in contrast to dendritic cell-derived exosomes efficiently used as 
immunogenic entities in vaccination experiments, blood-borne PMN-ectosomes might act as 
“anti-adjuvant”, that is to say circulating immunomodulatory microparticles one could use to 
suppress or dampen the immune system25-28. Preliminary experiments (O. Gasser, unpublished 
results) using dendritic cells seem to justify the contention that ectosome-functions are not 
restricted to monocyte/macrophages and thus that ectosomes might affect the immune status 
long after their release during acute inflammation.  
 
The effect of PMN-ectosomes on dendritic cells has to be confirmed and investigation on the 
molecular mechanisms ectosomes use to modulate the biology of macrophages and other 
immune cells might more precisely define the functional similarities and discrepancies 
between ectosomes and apoptotic cells. Whether PMN-ectosomes carry out more functions is 
an open question. The multitude of proteins expressed on their surface, with certainly more to 
 86
be identified, support this hypothesis. One might speculate that the enzymes present on the 
surface of ectosomes might carry out various functions: elastase might play a role in 
hemostasis, matrix metalloproteinase-9 in extracellular matrix remodelling and 
myeloperoxidase in antimicrobial defence. The multitude of possible functions of PMN-
ectosomes is further extended by the various binding sites that might be targeted by the 
receptors/ligands expressed on their surface. Complete proteomic- and exhaustive binding-
analyses as well as in vivo models will be necessary to gain more insight into ectosome’s very 
interesting biology.  
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